NRAS and acute myeloid leukemia: An extensive analysis carried out on 533 NPM1-mutated AML patients showed some notable differences in the mutational profile of patients ≤65 vs. ≥65 years: TET2 (13% vs. 27%), NRAS (13% vs. 7%), SRSF2 (5% vs. 15%), WT1 (10% vs. 4%), and ASXL1 (1% vs. 7%) [20].